Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7608143 | 0.94 | ALDH1A1 (0.49) | ALDH1A1DDB1CRBNMEN1KMT2A | |
| SCHEMBL24471399 | 0.88 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBN | |
| SCHEMBL595870 | 0.74 | DDB1 (0.51) | ALDH1A1DDB1CRBNKMT2A | |
| SCHEMBL3555789 | 0.74 | DDB1 (0.51) | ALDH1A1DDB1CRBNKMT2A | |
| SCHEMBL21952209 | 0.74 | DDB1 (0.43) | ALDH1A1DDB1CRBNMEN1KMT2A | |
| SCHEMBL28366851 | 0.74 | DDB1 (0.43) | ALDH1A1DDB1CRBNMEN1KMT2A | |
| SCHEMBL5355188 | 0.74 | KMT2A (0.51) | ALDH1A1DDB1CRBNMEN1KMT2A | |
| SCHEMBL18493339 | 0.73 | DDB1 (0.54) | ALDH1A1DDB1CRBNKMT2A | |
| SCHEMBL1200111 | 0.73 | DDB1 (0.54) | ALDH1A1DDB1CRBNKMT2A | |
| SCHEMBL16407806 | 0.73 | ALDH1A1 (0.47) | ALDH1A1DDB1CRBNMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
| US-6420418-B1 | INHIBITION AND PREVENTION OF LEUKOCYTE ADHESION; USED TO TREAT ADHESION-MEDIATED DISEASES SUCH AS ASTHMA, ALLERGIC RHINITIS, MULTIPLE SCLEROSIS; ATHEROSCLEROSIS, AND INFLAMMATORY BOWEL DISEASE | MERCK & CO., INC. | 2002-07-16 | — | — | US | disclosed |
| WO-2001012183-A1 | HETEROCYCLE AMIDES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | ALDH1A1 2943/4885DDB1 2333/4885CRBN 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.